A systematic literature review and meta-analysis was conducted to evaluate whether the administration of an oxytocin receptor antagonist (OTR-a) around embryo transfer is associated with live birth and pregnancy achievement in IVF treatment. Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil. The literature search identified 11 eligible RCT. The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3). Clinical pregnancy rate was significantly higher in women receiving an OTR-a around embryo transfer (relative risk [RR] 1.31, 95% confidence interval [CI] 1.13–1.51, P = 0.0002, I² = 61%, n = 11 studies, n = 3611); however, live birth rate was not statistically significantly affected (RR 1.09, 95% CI 0.98–1.20, P = 0.11, I² = 25%, n = 5 studies, n = 2765). A sensitivity analysis on low risk of bias studies likewise indicates a higher clinical pregnancy chance (RR 1.11, 95% CI 1.01–1.22, P = 0.03, I² = 5%, n = 5 RCT, n = 2765). OTR-a administration in IVF treatment has the potential to increase IVF efficacy, although the treatment effects observed so far are small and have not been sufficiently corroborated.

进行了系统的文献回顾和荟萃分析，以评估在胚胎移植期间施用催产素受体拮抗剂 (OTR-a) 是否与 IVF 治疗中的活产和妊娠成功相关。搜索多个数据库的随机对照试验 (RCT)，比较 IVF 治疗结果与胚胎移植之前、期间或之后施用 OTR-a 与施用安慰剂/无。文献检索确定了 11 项符合条件的 RCT。活性化合物是静脉注射阿托西班 ( n  = 7)、皮下注射巴鲁西班 ( n  = 1) 和口服诺拉西班 ( n = 3)。在胚胎移植前后接受 OTR-a 的女性临床妊娠率显着更高（相对风险 [RR] 1.31，95% 置信区间 [CI] 1.13–1.51，P  = 0.0002，I ²  = 61%，n  = 11 项研究，n  = 3611); 然而，活产率没有显着影响（RR 1.09, 95% CI 0.98–1.20, P  = 0.11, I ²  = 25%, n  = 5 项研究, n  = 2765）。对低偏倚风险研究的敏感性分析同样表明临床妊娠机会更高（RR 1.11, 95% CI 1.01–1.22, P  = 0.03, I ²  = 5%, n = 5 项随机对照试验，n  = 2765）。IVF 治疗中的 OTR-a 给药具有提高 IVF 疗效的潜力，尽管迄今为止观察到的治疗效果很小并且尚未得到充分证实。